The biology of type 2 diabetes and obesity has always been intertwined, but for decades clinical research treated them as separate specialties — glycemic control on one side, weight management on the other. The GLP-1 era finally forced an integration that reflects the underlying pathophysiology: the drugs controlling blood sugar are the same drugs reducing weight, and the trials testing them are capturing both outcomes simultaneously. What's coming next — triple agonists, oral GLP-1 peptides, stem cell therapies for type 1 — makes the current landscape look like chapter one of a much longer story.
This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Diabetes and obesity are among the most heavily researched conditions in medicine in 2026, propelled by the transformative success of GLP-1 receptor agonists. Tirzepatide produced 22.5% average weight loss in the SURMOUNT-1 trial — approaching bariatric surgery outcomes in a drug. Beyond semaglutide and tirzepatide, the next generation includes oral GLP-1 compounds, triple receptor agonists, amylin analogs, and SGLT2 inhibitor combination regimens in late-stage Phase 3 trials. For type 1 diabetes, stem cell-derived beta cell therapies have achieved insulin independence in early patients — a result that would have seemed impossible a decade ago.
ClinicalMetric Analysis
- Type 1 diabetes stem cell-derived beta cell transplant results (VX-880, Vertex) with insulin independence in early patients are the most transformative early-stage data in T1D in decades — but the immunosuppression requirement is the limiting factor that currently restricts this to a narrow high-risk population. Patients who achieve insulin independence with VX-880 require the same immunosuppressive regimen as solid organ transplant recipients — tacrolimus, mycophenolate, and associated infection and malignancy risks. This is currently appropriate only for patients with severe hypoglycemia unawareness whose quality of life risk from undetected hypoglycemic episodes exceeds the immunosuppression risk profile. The encapsulated cell approach (VX-264), designed to eliminate the need for systemic immunosuppression by protecting cells in a semipermeable device, is the critical next step for expanding eligibility beyond this narrow indication.
- The FLOW trial's semaglutide result — 24% reduction in kidney disease progression events in T2D+CKD — means GLP-1 agonists now have three independent organ-protection mechanisms beyond glycemic control, and prescribing based on HbA1c alone is clinically incomplete. Semaglutide has demonstrated cardiovascular risk reduction (SELECT, LEADER), kidney disease protection (FLOW), and weight loss with associated metabolic benefits. T2D patients with any of cardiovascular disease, obesity, or CKD should be considered for GLP-1 agonist therapy as a priority — not as glycemic add-on therapy after metformin failure, but as first- or second-line therapy chosen for organ-protection rationale. The prescribing pattern that treats GLP-1 agonists as "the next step after metformin inadequacy" is misaligned with the evidence that's now accumulated.
- Oral GLP-1 formulations are the access mechanism that determines whether GLP-1 benefits extend globally — and amycretin's Phase 1 weight loss data (13.1% at 12 weeks) is particularly significant because that efficacy in an oral form addresses the cold chain and injection barriers that currently restrict injectable GLP-1 to well-resourced settings. Weekly injectable semaglutide and tirzepatide require cold chain storage and injection infrastructure that is feasible in high-income countries but structurally inaccessible in health systems across Sub-Saharan Africa, South Asia, and rural low-income settings globally. Oral formulations stable at room temperature, taken as tablets, eliminate these barriers. If Phase 3 amycretin data replicates the Phase 1 weight loss signal, it would represent genuine access democratization for the largest single-disease burden GLP-1 technology addresses.
The GLP-1 Revolution and What Comes Next
Tirzepatide (Mounjaro/Zepbound, Eli Lilly) — a dual GLP-1/GIP receptor agonist — produced average weight loss of 22.5% in the SURMOUNT-1 Phase 3 trial at 72 weeks with 15 mg weekly, with 63% of participants achieving at least 20% weight loss. To put that in clinical context: the standard threshold for "clinically meaningful" weight loss has been 5–10%. Tirzepatide is consistently producing two to four times that. The SELECT trial for semaglutide showed a 20% reduction in major adverse cardiovascular events in people with obesity without diabetes — an entirely new indication that reshapes how obesity is classified medically.
The FLOW trial demonstrated that once-weekly semaglutide 1 mg reduced major kidney disease progression events by 24% in patients with type 2 diabetes and chronic kidney disease — an indication where the drug's benefit extends far beyond glycemic control. The drug now has regulatory approval for cardiovascular risk reduction, kidney disease progression reduction, and both T2D and obesity management. That's an unusual breadth of indication for any single compound.
In 2026, the pipeline has advanced beyond these: retatrutide (GLP-1/GIP/glucagon triple agonist, Eli Lilly) produced 24.2% average weight loss at 48 weeks in Phase 2 — the highest ever recorded for any pharmacological intervention. The Phase 3 TRIUMPH program is enrolling patients with obesity (BMI ≥30) or overweight with comorbidities. Amycretin (oral GLP-1/amylin dual agonist, Novo Nordisk) showed 13.1% weight loss at 12 weeks in early Phase 1 data — extraordinary for an oral compound — and has entered Phase 3.
Oral GLP-1 Programs: The Transition from Injectable
The transition from injectable to oral GLP-1 is one of the most commercially significant pharmaceutical developments in a generation. Oral semaglutide (Rybelsus) is approved for type 2 diabetes, and the OASIS Phase 3 program is evaluating higher doses (25 mg, 50 mg daily) for obesity — doses that require specific administration conditions (fasting, small water volume) due to the absorption pharmacology of the peptide formulation.
Orforglipron (Eli Lilly, a small-molecule non-peptide GLP-1 agonist) avoids these constraints entirely — it can be taken without fasting or water restrictions because it isn't a peptide. Phase 2 showed dose-dependent weight loss of 8.6–12.6% at 36 weeks, and Phase 3 cardiovascular and diabetes outcome trials are now enrolling. This is where it gets interesting for the access question: a once-daily pill with no dietary restrictions around dosing would remove a significant adherence barrier that even motivated patients struggle with on peptide formulations.
Danuglipron (Pfizer) was discontinued after Phase 2 due to nausea and vomiting rates — a reminder that tolerability, not just efficacy, determines what reaches patients. The orforglipron data suggests the small molecule approach can hit GLP-1 efficacy while improving tolerability, but the Phase 3 data will be definitive.
SGLT2 Inhibitors: Expanding Well Beyond Diabetes
Sodium-glucose cotransporter-2 inhibitors — empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana) — have demonstrated cardiovascular and renal protective effects independent of glycemic control, fundamentally reshaping how they're prescribed. The EMPA-KIDNEY trial showed empagliflozin reduced progression of CKD by 28% regardless of whether patients had diabetes. In 2026, trials are testing SGLT2 inhibitors in heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatohepatitis (MASH), and atrial fibrillation prevention — extending their reach far beyond the diabetology clinic.
Combination trials pairing SGLT2 inhibitors with GLP-1 agonists are asking whether the two complementary mechanisms — GLP-1 reducing caloric intake and improving beta cell function; SGLT2i promoting glucosuria and reducing cardiac and renal stress — produce additive cardiorenal benefits. The COMBINE-DKD Phase 3 trial is evaluating this combination specifically in diabetic kidney disease, a population with high residual risk despite current standard of care.
Type 1 Diabetes: Beta Cell Preservation and Restoration
Type 1 diabetes research has a different focus from T2D — it centers on preserving residual beta cell function at diagnosis, preventing disease in at-risk individuals (Stage 1 and Stage 2 T1D), and eventually restoring insulin independence. Teplizumab (Tzield) — an anti-CD3 antibody that delays T1D onset by approximately 3 years in Stage 2 disease — received FDA approval in November 2022, validating immune intervention in presymptomatic T1D. This changed how T1D is screened and monitored in relatives of affected patients.
Stem cell-derived beta cell therapies represent the most ambitious approach. Vertex Pharmaceuticals' VX-880 — fully differentiated stem cell-derived islet cells implanted without encapsulation — has produced insulin independence in a subset of early patients in Phase 1/2 FORWARD trial. VX-264 (same cells in an immunoprotective device designed to eliminate the need for systemic immunosuppression) is in Phase 1. These programs are recruiting T1D patients who lack hypoglycemia awareness or have severe hypoglycemic episodes — patients for whom the risk-benefit of immunosuppression or a surgical procedure is justified by the severity of their current situation.
How to Find and Enroll in Diabetes and Obesity Trials
Key eligibility factors to know before searching: your HbA1c (typical range 7.0–10.5% for most T2D trials), BMI (most obesity trials require ≥27 with a comorbidity or ≥30 without), current medications (GLP-1 agonist or SGLT2i use may be exclusionary or required depending on the study design), and history of cardiovascular events or CKD (required for some outcome trials).
Industry-sponsored trials for novel GLP-1 compounds frequently run at community endocrinology practices and suburban research clinics — not just major academic centers. This makes geographic access considerably easier than for oncology or rare disease trials. The American Diabetes Association (diabetes.org) and Obesity Medicine Association both maintain patient-facing information about active research programs. Telling your endocrinologist or primary care physician that you're interested in trial participation is the most direct path to enrollment at community sites that don't advertise publicly.
Key Takeaways
- Retatrutide (triple GLP-1/GIP/glucagon agonist) achieved 24.2% weight loss in Phase 2 — the highest ever pharmacologically — with Phase 3 TRIUMPH trials now enrolling patients with obesity or overweight with comorbidities.
- Oral GLP-1 programs (orforglipron, amycretin, high-dose oral semaglutide) are in Phase 3 targeting patients who prefer non-injectable options; typical eligibility: BMI ≥27 with one comorbidity or ≥30 without.
- SGLT2 inhibitor trials are expanding to HFpEF, MASH, and atrial fibrillation prevention; COMBINE-DKD is evaluating SGLT2i plus GLP-1 combination therapy in diabetic kidney disease.
- Vertex VX-880 and VX-264 stem cell-derived beta cell therapies are in Phase 1/2 for T1D patients with severe hypoglycemia — early results include insulin independence in a subset of patients.
- Diabetes and obesity trials frequently run at community endocrinology practices — making geographic access significantly easier than most other trial categories.